U.S. Pharmaceuticals & Biotech Mid-Large Cap Stocks

Pfizer

Market Cap: US$137.0b

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.

Johnson & Johnson

Market Cap: US$425.5b

Engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide.

Merck

Market Cap: US$199.0b

Operates as a healthcare company worldwide.

Bristol-Myers Squibb

Market Cap: US$89.9b

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

Gilead Sciences

Market Cap: US$141.0b

A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Amgen

Market Cap: US$150.3b

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.

Perrigo

Market Cap: US$2.9b

Provides over-the-counter health and wellness solutions in the United States, Europe, and internationally.

AbbVie

Market Cap: US$388.6b

A research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide.

Phibro Animal Health

Market Cap: US$1.6b

Operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific.

Agilent Technologies

Market Cap: US$35.3b

Provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide.

Zoetis

Market Cap: US$62.8b

Engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally.

Viatris

Market Cap: US$11.3b

Operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East.

Qiagen

Market Cap: US$9.8b

Provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally.

Royalty Pharma

Market Cap: US$20.9b

Operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.

Eli Lilly

Market Cap: US$666.0b

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally.

Organon

Market Cap: US$2.7b

Develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally.

Atai Life Sciences

Market Cap: US$1.2b

A clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada.

Avantor

Market Cap: US$8.2b

Engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa.

Tourmaline Bio

Market Cap: US$1.2b

Operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases.

Centessa Pharmaceuticals

Market Cap: US$3.2b

A clinical-stage pharmaceutical company, discovers, develops, and delivers medicines.

Axsome Therapeutics

Market Cap: US$5.9b

A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.

LENZ Therapeutics

Market Cap: US$1.2b

Operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States.

BioNTech

Market Cap: US$24.0b

A biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany.

Alnylam Pharmaceuticals

Market Cap: US$60.1b

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference.

Travere Therapeutics

Market Cap: US$2.2b

A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.

Arcus Biosciences

Market Cap: US$1.3b

A clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.

BioLife Solutions

Market Cap: US$1.2b

Develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally.

Madrigal Pharmaceuticals

Market Cap: US$9.5b

A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.

Vaxcyte

Market Cap: US$4.3b

A clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.

Anbio Biotechnology

Market Cap: US$1.6b

Provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally.

Revolution Medicines

Market Cap: US$8.1b

A clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.

Ascendis Pharma

Market Cap: US$11.7b

Operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally.

Soleno Therapeutics

Market Cap: US$3.4b

A clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.

Exelixis

Market Cap: US$10.5b

An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.

Tempus AI

Market Cap: US$13.8b

Operates as a healthcare technology company.

Corcept Therapeutics

Market Cap: US$8.8b

Engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.